Header Image

Latest News

Latest News

Filter Releases
 
Latest News
Date Title and Summary View
May 27, 2014
Significant reduction in HAE attacks by 0.45 per week versus placebo (p...
May 24, 2014
RESEARCH TRIANGLE PARK, N.C., May 24, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX) today announced that management plans to report results for the OPuS-1 (Oral ProphylaxiS-1) proof of concept Phase 2a clinical trial of orally-administered BCX4161 in patients with hereditary angioedema (HAE) the morning of Tuesday, May 27, ...
May 9, 2014
RESEARCH TRIANGLE PARK, N.C., May 9, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that its executives are scheduled to present a corporate summary and update regarding the Company's development programs at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas on Tuesday, May 13, 2014 at 3:00 p...
May 8, 2014
RESEARCH TRIANGLE PARK, N.C., May 8, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the first quarter ended March 31, 2014. "We have completed enrollment in the OPuS-1 Phase 2 trial to evaluate orally-administered BCX4161 in patients with hereditary angioedema and we look forward ...
Apr 28, 2014
RESEARCH TRIANGLE PARK, N.C., April 28, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that its first quarter 2014 financial results will be released on Thursday, May 8, 2014. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial results and to provide an update o...
Mar 3, 2014
RESEARCH TRIANGLE PARK, N.C., March 3, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the online publication in the journal NatureĀ of extensive laboratory and nonclinical characterizations of BCX4430, including efficacy results in animal models of infection with Marburg virus and Ebola virus, two highly virule...
Mar 1, 2014
RESEARCH TRIANGLE PARK, N.C., March 1, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) announced the presentation of two scientific posters today at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Diego describing phase 1 clinical trial results for BioCryst's potent and selective oral kallikr...
Feb 26, 2014
RESEARCH TRIANGLE PARK, N.C., Feb. 26, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the fourth quarter and full year ended December 31, 2013. "Since our last quarterly results update, we have initiated the OPuS-1 Phase 2 trial to evaluate orally-administered BCX4161 in patients ...
Feb 25, 2014
RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA...
Feb 20, 2014
RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company's clinical programs at the following investor conferences: The Cowen and Company 34th Annual Health Care Conference...
Feb 12, 2014
RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that its fourth quarter and full year 2013 financial results will be released on Wednesday, February 26, 2014. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial results and t...
Jan 2, 2014
RESEARCH TRIANGLE PARK, N.C., Jan. 2, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that its executives are scheduled to present a corporate summary and update regarding the Company's development programs at the 32nd annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16th, 2014 at ...
Dec 30, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised an option to conduct the investigational new drug (IND) enabling program and to submit an IND. This option repr...
Dec 20, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous...
Dec 18, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it has selected two optimized plasma kallikrein inhibitors to advance into preclinical development as potential once-daily, oral treatments for the prevention of hereditary angioedema (HAE) a...
Page: First Previous
...
...
Next Last